Catechol-O-methyltransferase inhibition improves set-shifting performance and elevates stimulated dopamine release in the rat prefrontal cortex

Journal of Neuroscience

Volumn 24, Issue 23, 2004, Pages 5331-5335

  Tunbridge, Elizabeth M ^a,b   Bannerman, D M ^a   Sharp, T ^a   Harrison, P J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WARNEFORD HOSPITAL   (United Kingdom)

Author keywords

Antipsychotic; Catecholamine; Clozapine; Norepinephrine; Tolcapone; Working memory

Indexed keywords

CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CATECHOLAMINE; CLOZAPINE; DOPAMINE; METHIONINE; NEUROLEPTIC AGENT; NEUROMUSCULAR DEPOLARIZING AGENT; NORADRENALIN; POTASSIUM CHLORIDE; TOLCAPONE; VALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTION DEFICIT DISORDER; CELL TRANSPORT; COMT GENE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG BRAIN LEVEL; DRUG PENETRATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE; MALE; MICRODIALYSIS; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA; SET SHIFTING PERFORMANCE; TASK PERFORMANCE;

ANIMALS; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CATECHOLAMINES; CLOZAPINE; DOPAMINE; ENZYME INHIBITORS; MICRODIALYSIS; NITROPHENOLS; NOREPINEPHRINE; PREFRONTAL CORTEX; RATS; SCHIZOPHRENIA; SEROTONIN ANTAGONISTS; SYNAPTIC TRANSMISSION;

EID: 2942614921     PISSN: 02706474     EISSN: None     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.1124-04.2004     Document Type: Article

References (40)

1. Acquas E, Carboni E, de Ree RHA, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 59:326-330.
2. Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicot JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M (2003) Differential effect of COMT Val108/158 Met genotype on enhancement of prefrontal cortical function and working memory in patients with schizophrenia treated with olanzapine. Soc Neurosci Abstr 29:881.5.
3. Birrell J, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320-4324.
4. 18F-Dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43:201-207.
5. Crofts HS, Dalley JW, Collins P, Van Denderen JCM, Everitt BJ, Robbins TW, Roberts AC (2001) Differential effect of 6-OHDA lesions of the frontal cortex and caudate nucleus on the ability to acquire an attentional set. Cereb Cortex 11:1015-1026.
6. Dias R, Robbins TW, Roberts AC (1996a) Primate analogue of the Wisconsin card sorting test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci 110:872-876.
7. Dias R, Robbins TW, Roberts AC (1996b) Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380:69-72.
8. Downes JJ, Roberts AC, Sahakian BJ, Evenden JL, Morris RG, Robbins TW (1989) Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 27:1329-1343.
9. 108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98:6917-6922.
10. Fox MT, Barense MD, Baxter MG (2003) Perceptual attentional set-shifting is impaired in rats with neurotoxic lesions of posterior parietal cortex. J Neurosci 23:676-681.
11. Gaspirini M, Fabrizio E, Bonifati V, Meco G (1997) Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm 104:887-894.
12. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, Karayiorgou M (1998) Catechol-O-methlytransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behaviour. Proc Natl Acad Sci USA 95:9991-9996.
13. Khromova I, Voronina T, Kraineva VA, Zolotov N, Männisto PT (1997) Effect of selective catechol-O-methyltransferase inhibitor on single-trial passive avoidance retention in male rats. Behav Brain Res 86:49-57.
14. Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM (1996) Human catechol-O-methlytransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
15. Liljequist R, Haapalinna A, Ahlander M, Li YH, Männisto PT (1997) Catechol-O-methyltransferase inhibitor tolcapone has minor influence on performance in experimental memory models in rats. Behav Brain Res 82:195-202.
16. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melén K, Julkunen I, Taskinen J (1995) Kinetics of human soluble and membrane-bound catechol-O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34:4202-4210.
17. Manes F, Sahakian B, Clark L, Rogers R, Antoun N, Aitken M, Robbins T (2002) Decision-making processes following damage to the prefrontal cortex. Brain 125:624-639.
18. Männisto PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593-628.
19. Matsumoto M, Weickert CS, Akil M, Lipska BK, Hyde TM, Herman MM, Weinberger DR, Kleinman JE (2003) Catechol-O-methyltransferase mRNA expression in human and rat brain: evidence for a role in cortical neuronal function. Neuroscience 116:127-137.
20. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, Kolachana B, Callicott JH, Weinberger DR (2003) Catechol-O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 100:6186-6191.
21. McTavish SFB, Callado L, Cowen PJ, Sharp T (1999) Comparison of the effects of α-methyl-p-tyrosine and a tyrosine-free amino acid load on extracellular noradrenaline in the rat hippocampus in vivo. J Psychopharmacol 13:379-384.
22. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
23. Middleton HC, Sharma A, Agouzoul D, Sahakian BJ, Robbins TW (1999) Idazoxan potentiates rather than antagonizes some of the cognitive effects of clonidine. Psychopharmacology (Berl) 145:401-411.
24. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755-1760.
25. Nagahama Y, Okada T, Katsumi Y, Hayashi T, Yamauchi H, Oyanagi C, Konishi J, Fukuyama H, Shibasaki H (2001) Dissociable mechanisms of attentional control within the human prefrontal cortex. Cereb Cortex 11:85-92.
26. Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. San Diego: Academic.
27. Ragozzino ME (2002) The effects of dopamine D1 receptor blockade in the prelimbic-infralimbic areas on behavioural flexibility. Learn Mem 9:18-28.
28. Reid L, Egerton A, Morris BJ, Pratt A (2003) Acute PCP administration produces an attention set shifting deficit and reduced neural activity in the medial frontal cortex of the rat. Soc Neurosci Abstr 29:940.11.
29. Roberts AC, Robbins TW, Everitt BJ (1988) Extra-dimensional versus intradimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29:993-1006.
30. Roberts AC, De Salvia MA, Wilkinson LS, Collins P, Muir JL, Everitt BJ, Robbins TW (1994) 6-Hydroxydopamine lesions of the prefrontal cortex in monkeys enhance performance on an analog of the Wisconsin card sort test: possible interaction with subcortical dopamine. J Neurosci 4:2531-2544.
31. Rogers RD, Blackshaw AJ, Middleton HC, Matthews K, Hawtin K, Crowley C, Hopwood A, Wallace C, Deakin JF, Sahakian BJ, Robbins TW (1999) Tryptophan depletion impairs stimulus-reward learning while methylphenidate disrupts attentional control in healthy young adults: implications for the monoaminergic basis of impulsive behaviour. Psychopharmacology (Berl) 146:482-491.
32. Rogers RD, Andrews TC, Grasby PM, Brooks DJ, Robbins TW (2000) Contrasting cortical and subcortical activations produced by attentional-set shifting and reversal learning in humans. J Cognit Neurosci 12:142-162.
33. Sesack SR, Hawrylak VA, Matus C, Guido MA, Levey AI (1998) Dopamine axon varicositites in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter. J Neurosci 18:2697-2708.
34. Shifman S, Bronstein M, Strenfeld M, Pisanté-Shalom A, Lev-Lehman E, Weizman A, Reznik I, Spivak B, Grisaru N, Karp L, Schiffer R, Kotler M, Strous RD, Swartz-Vanetik M, Knobler HY, Shinar E, Beckmann JS, Yakir B, Risch N, Zak NB, Darvasi A (2002) A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 71:1296-1302.
35. Ulmanen I, Peränen J, Tenhunen J, Tilgmann C, Karhunen T, Panula P, Bernasconi L, Aubry JP, Lundstrom K (1997) Expression and intracellular localization of catechol-O-methyltransferase in transfected mammalian cells. Eur J Biochem 243:452-459.
36. Watanabe M, Kodama T, Hikosaka K (1997) Increase of extracellular dopamine in primate prefrontal cortex during a working memory task. J Neurophysiol 78:2795-2798.
37. Wilkinson LS, Humby T, Killcross AS, Torres EM, Everitt BJ, Robbins TW (1998) Dissociations in dopamine release in medial prefrontal cortex and ventral striatum during the acquisition and extinction of classical aversive conditioning in the rat. Eur J Neurosci 10:1019-1026.
38. Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine DI receptors in prefrontal cortex. Nature 376:572-574.
39. Zahrt J, Taylor JR, Mathew RG, Arnsten AFT (1997) Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs working memory performance. J Neurosci 17:8528-8535.
40. Zürcher G, Keller HH, Kettler R, Borgulya J, Bonetti EP, Eigenmann R, Da Prada M (1990) Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 53:497-503.